Drugs / ABIPAPOGENE SUVAPLASMID
ABIPAPOGENE SUVAPLASMID
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06016920 | Dec 2023 → Sep 2027 expected | oropharynx squamous cell carcinoma | Nykode Therapeutics ASA | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02529930 | Aug 2015 → Jan 2019 | cervical intraepithelial neoplasia grade 2/3 | Nykode Therapeutics ASA | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06099418 | Apr 2024 → May 2027 | cervical carcinoma, virus associated tumor | Nykode Therapeutics ASA | Withdrawn | No outcome recorded |
| Phase 2 | NCT04405349 | Jul 2020 → Nov 2023 | cervical cancer | Nykode Therapeutics ASA | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABIPAPOGENE SUVAPLASMID | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068196 ↗ |
| Known as | Abipapogen suvaplasmido | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068196 ↗ |
| Known as | VB10.16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04405349 ↗ |
| Modality | Vaccine | “VB10.16 Immunotherapy (DNA vaccine)” NCT02529930 ↗ |
| Route | Intramuscular | “VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.” NCT02529930 ↗ |